A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Response Study to Evaluate the Efficacy and Safety of E6742 in Subjects With Systemic Lupus Erythematosus

Eisai Clinical Trials

Protocol # E6742-G000-201

Study Overview

Study Compound: E6742

Drug Name:

Registry #: NCT07515014

Trial Period: Mar 2026 - Mar 2029

Indication: Systemic Lupus Erythematosus

Primary Endpoint: 1. Percentage of Participants who Achieve a BICLA Response with Low Dose of OCS (Prednisone or Equivalent) at Week 24 [Time Frame: At Week 24]

Population
Males and females 18 Years to 75 Years (Adult, Older Adult)
Study Status
Not started
Study Phase
Phase 2
Countries
China, Japan, Korea, Republic of, Philippines, Taiwan, United States See moreSee less

Clinical Trial Documents

Clinical Study Report Synopsis

No download available

Plain Language Protocol Synopsis (PLPS)

Download PDF

Plain Language Summary of Results (PLS)

No download available

Publication reference citation

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

CSDR Sharing is not available for this study.

CSDR	Availability
Clinical Trial Data

Redacted documents may be available upon request for this study.

Document type	Availability
Protocol
SAP
Sample CRF
Full CSR